[go: up one dir, main page]

WO2008152422A3 - Protéines de liaison spécifiques pour des facteurs de croissance de type insuline et leurs utilisations - Google Patents

Protéines de liaison spécifiques pour des facteurs de croissance de type insuline et leurs utilisations Download PDF

Info

Publication number
WO2008152422A3
WO2008152422A3 PCT/GB2008/050436 GB2008050436W WO2008152422A3 WO 2008152422 A3 WO2008152422 A3 WO 2008152422A3 GB 2008050436 W GB2008050436 W GB 2008050436W WO 2008152422 A3 WO2008152422 A3 WO 2008152422A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding proteins
insulin
growth factors
proteins specific
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/050436
Other languages
English (en)
Other versions
WO2008152422A2 (fr
Inventor
Vahe Bedian
Susan Ann Cartlidge
Gadi Gazit-Bornstein
Olivia Raeber
David William Tonge
Xiao-Dong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Publication of WO2008152422A2 publication Critical patent/WO2008152422A2/fr
Publication of WO2008152422A3 publication Critical patent/WO2008152422A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des protéines de liaison, telles que des anticorps dirigés contre IGF-II avec une réactivité croisée vis-à-vis de IGF-I, et les utilisations de tels anticorps.
PCT/GB2008/050436 2007-06-12 2008-06-11 Protéines de liaison spécifiques pour des facteurs de croissance de type insuline et leurs utilisations Ceased WO2008152422A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94333107P 2007-06-12 2007-06-12
US60/943,331 2007-06-12

Publications (2)

Publication Number Publication Date
WO2008152422A2 WO2008152422A2 (fr) 2008-12-18
WO2008152422A3 true WO2008152422A3 (fr) 2009-03-12

Family

ID=39671449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050436 Ceased WO2008152422A2 (fr) 2007-06-12 2008-06-11 Protéines de liaison spécifiques pour des facteurs de croissance de type insuline et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2008152422A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CA2740341C (fr) 2008-12-12 2019-05-07 Boehringer Ingelheim International Gmbh Anticorps anti-igf
EP3450454A1 (fr) 2010-07-22 2019-03-06 John W. Schrader Protection croisée contre l'infection par le virus de la grippe
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
JP2017502025A (ja) * 2013-12-19 2017-01-19 メディミューン，エルエルシー 肉腫を治療するための組成物および方法
CN114984192A (zh) * 2022-06-29 2022-09-02 重庆大学 重组蛋白igf1-24在制备治疗呼吸功能障碍的药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505075A1 (fr) * 2002-04-30 2005-02-09 Kyowa Hakko Kogyo Co., Ltd. Anticorps pour facteur de croissance humain semblable a l'insuline
WO2005016970A2 (fr) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
EP1661582A1 (fr) * 2003-08-21 2006-05-31 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de metastase cancereuse
WO2007070432A2 (fr) * 2005-12-13 2007-06-21 Astrazeneca Ab Proteines de liaison specifiques des facteurs de croissance analogues a l'insuline et utilisations de celles-ci

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505075A1 (fr) * 2002-04-30 2005-02-09 Kyowa Hakko Kogyo Co., Ltd. Anticorps pour facteur de croissance humain semblable a l'insuline
WO2005016970A2 (fr) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
EP1661582A1 (fr) * 2003-08-21 2006-05-31 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de metastase cancereuse
WO2007070432A2 (fr) * 2005-12-13 2007-06-21 Astrazeneca Ab Proteines de liaison specifiques des facteurs de croissance analogues a l'insuline et utilisations de celles-ci

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOYA MASATO ET AL: "Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 64, no. 17, 1 January 2004 (2004-01-01), pages 6252 - 6258, XP002982679, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2008152422A2 (fr) 2008-12-18

Similar Documents

Publication Publication Date Title
WO2010145792A8 (fr) Protéines bispécifiques se liant à un antigène
WO2009036448A3 (fr) Agonistes des récepteurs peptidiques natriurétiques de type c
IL191718A0 (en) Binding proteins specific for insulin-like growth factors and uses thereof
WO2009099641A3 (fr) Compositions protéiniques stabilisées
AU2009209251A8 (en) Stabilized Angiopoietin-2 antibodies and uses thereof
WO2008157356A3 (fr) Formulations d'anticorps
ZA201200724B (en) Specific sorbent for binding proteins and peptides, and separation method using the same
EP2304440A4 (fr) Nouveaux anticorps monoclonaux dirigés contre des protéines du hpv
IL220471A0 (en) Specific sorbent for binding proteins and peptides, and separation method using the same
WO2010121093A3 (fr) Compositions d'anticorps humanisés et procédés de liaison d'acide lysophosphatidique
WO2008133722A3 (fr) Anticorps et diagnostics
WO2007084321A3 (fr) Anticorps dirigés contre ox-2/cd200 et utilisations correspondantes
WO2009149956A3 (fr) Protéine de fusion et son utilisation
WO2011056644A3 (fr) Anticorps anti-glp-1r et leurs utilisations
WO2008048519A3 (fr) Anticorps se liant aux épitopes de cxcr7
WO2009028625A1 (fr) Procédé de liaison d'une protéine à un support à l'aide de tamavidine
WO2008152422A3 (fr) Protéines de liaison spécifiques pour des facteurs de croissance de type insuline et leurs utilisations
WO2010142551A3 (fr) Séquences d'acides aminés dirigées contres les récepteurs des cytokines appartenant à la famille il-17
WO2010136483A3 (fr) Protéines de liaison à l'antigène
WO2011131510A3 (fr) Modification sélective de protéines
WO2011055897A3 (fr) Protéine de fusion se liant spécifiquement à une région constante d'un anticorps, préparation associée et procédé d'isolement d'anticorps l'utilisant
WO2013124482A9 (fr) Identification de modulateurs des propriétés de liaison d'anticorps réagissant avec un membre de la famille des récepteurs d'insuline
WO2010063833A3 (fr) Complexe de protéines favorisant la croissance des plantes
WO2009135953A3 (fr) Séquences d'acides aminés dirigées contre des intégrines et leurs utilisations
WO2010127180A3 (fr) Anticorps anti-dc-stamp

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08762546

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08762546

Country of ref document: EP

Kind code of ref document: A2